Equities

ImmuCell Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert
ICCC:NAQ

ImmuCell Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)6.30
  • Today's Change-0.24 / -3.67%
  • Shares traded16.14k
  • 1 Year change+22.09%
  • Beta0.2993
Data delayed at least 15 minutes, as of Mar 03 2026 19:09 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).

  • Revenue in USD (TTM)27.77m
  • Net income in USD2.32m
  • Incorporated1987
  • Employees70.00
  • Location
    ImmuCell Corp56 Evergreen DrivePORTLAND 04103United StatesUSA
  • Phone+1 (207) 878-2770
  • Fax+1 (302) 655-5049
  • Websitehttps://immucell.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Telomir Pharmaceuticals Inc0.00-11.25m42.63m----6.01-----0.3739-0.37390.000.20630.00-------266.47---303.19--------------0.00-------26.48------
BioScience Health Innovations Inc4.73m885.68k43.92m--206.5025.67--9.290.01940.01940.13130.15583.814.3099.37--71.34--85.11--63.64--18.74--3.47--0.00--208.73--134.59------
RADNOSTIX, INC.14.07m-231.26k47.54m41.00--11.60282.453.38-0.0004-0.00040.02680.00780.81475.968.18343,260.30-1.341.32-1.681.9559.8959.45-1.641.951.06-0.29280.59540.0013.319.19100.99--28.22--
Elutia Inc21.08m-22.99m48.68m51.00------2.31-0.6006-0.68270.5347-1.030.54194.046.50413,411.80-59.08-57.79---128.4145.9742.77-109.03-92.860.396-------1.50-10.69-31.23--2.54--
Odonate Inc0.00-102.07m52.65m137.00--2,022.38-----108.70-108.700.0074.170.00----0.00-66.98-58.36-83.00-65.14------------0.00-------12.99------
MindWalk Holdings Corp14.93m-22.66m53.23m102.00--4.06--3.57-0.6296-0.61130.350.28050.47456.674.50---72.01-32.32-90.53-36.4558.5055.79-151.78-100.974.09-23.680.17--0.008211.77-11.25--10.37--
Nasus Pharma Ltd0.00-1.19m53.63m-----------0.1319-0.13830.00-0.47620.00-------373.32-----------------2.51---------54.23------
LifeVantage Corp210.05m7.86m57.83m232.007.541.755.370.27530.59980.599816.162.583.242.4596.73905,370.7012.129.1718.9114.0878.7580.733.742.931.03--0.0035.0614.17-0.3794233.84-3.22-12.55--
ImmuCell Corp27.77m2.32m59.16m70.0025.271.9911.782.130.25880.25883.093.290.61591.9011.42402,453.605.15-5.355.69-5.7740.9336.028.37-11.871.766.470.2415--51.6414.0662.65---19.66--
Janel Corp212.13m5.02m61.37m353.0012.422.606.940.28934.174.17175.9919.891.4832.913.83600,929.203.971.7613.955.3332.0426.692.690.96080.70953.620.50200.0013.2420.272,155.61---14.58--
Scilex Holding Co40.36m-375.84m68.69m30.00------1.70-33.18-33.184.08-28.880.21457.271.85350,956.50-177.73------68.5975.06-828.56-176.540.0429-3.76----21.0721.8956.40---49.14--
Cumberland Pharmaceuticals, Inc.41.28m-3.33m72.39m91.00--2.7757.361.75-0.2331-0.23312.791.750.57881.723.80453,608.30-4.68-6.88-7.60-9.6584.4980.74-8.09-15.891.11-28.410.1688---4.261.95-3.19---29.32--
Rafael Holdings Inc1.03m-31.33m75.06m21.00--0.8917--72.94-0.8471-0.84710.02841.630.0107--3.3549,000.00-32.33-45.03-37.62-51.7589.70---3,034.89-8,772.743.98--0.0074--43.96-28.5111.30---47.65--
Assertio Holdings Inc137.35m-28.92m75.53m58.00--0.713834.220.5499-4.71-4.7120.9316.490.46111.351.472,368,138.00-9.71-15.74-17.07-24.1968.1682.29-21.06-42.011.43--0.2702---17.83-11.4593.50------
Data as of Mar 03 2026. Currency figures normalised to ImmuCell Corp's reporting currency: US Dollar USD

Institutional shareholders

11.39%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Dec 2025260.33k2.88%
Renaissance Technologies LLCas of 31 Dec 2025150.69k1.67%
Cresset Asset Management LLCas of 31 Dec 2025135.27k1.50%
Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Dec 2025124.72k1.38%
Bleichroeder LPas of 31 Dec 2025101.59k1.12%
Geode Capital Management LLCas of 31 Dec 202572.26k0.80%
Steadtrust LLCas of 31 Dec 202556.77k0.63%
Dimensional Fund Advisors LPas of 31 Dec 202546.01k0.51%
Vanguard Fiduciary Trust Co.as of 31 Dec 202542.67k0.47%
Dauntless Investment Group LLCas of 31 Dec 202539.63k0.44%
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.